Precision BioSciences (NASDAQ:DTIL) Announces Earnings Results

Precision BioSciences (NASDAQ:DTIL) issued its quarterly earnings results on Thursday. The company reported ($2.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($1.78), Zacks reports. The company had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $5.00 million. Precision BioSciences had a negative return on equity of 23.69% and a net margin of 11.48%.

Precision BioSciences Stock Performance

NASDAQ:DTIL opened at $4.71 on Friday. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.34. Precision BioSciences has a 12-month low of $3.61 and a 12-month high of $13.44. The stock has a 50-day moving average price of $5.01 and a 200 day moving average price of $5.52. The stock has a market capitalization of $49.69 million, a P/E ratio of 78.51 and a beta of 1.55.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $60.00 price target on shares of Precision BioSciences in a research report on Friday, March 28th.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.